MAPK1 and neoplasm: Next, we compared the duration of the OS and DFS periods between groups of patients with tumours that had: (1) mutations in genes of only one of the four MAPK pathway modules (i.e., the ERK1/2, ERK5, p38 or JNK pathways), (2) in genes of more than one of the MAPK pathway modules (3) or with no mutations in any MAPK pathway genes.